Optimizing hydroxyurea therapy for sickle cell anemia

Hematology (United States)

Volumn 2015, Issue 1, 2015, Pages 436-443

  Ware, Russell E ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA; ANTISICKLING AGENT;

ARTICLE; BLOOD TRANSFUSION; CEREBROVASCULAR DISEASE; HUMAN; IRON OVERLOAD; LONG TERM CARE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY (TOPIC); OPTIMAL DRUG DOSE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBOTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SICKLE CELL ANEMIA; TREATMENT INDICATION; ANEMIA, SICKLE CELL; CEREBROVASCULAR DISORDERS; DRUG ADMINISTRATION; FEMALE; GENOTYPE; GLOBAL HEALTH; HEALTH CARE DELIVERY; MALE; NATIONAL HEALTH ORGANIZATION; PRACTICE GUIDELINE; PREGNANCY; UNITED STATES;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD TRANSFUSION; CEREBROVASCULAR DISORDERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FETAL HEMOGLOBIN; GENOTYPE; GLOBAL HEALTH; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYDROXYUREA; IRON OVERLOAD; MALE; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); PHLEBOTOMY; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; UNITED STATES;

EID: 85039809697     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2015.1.436     Document Type: Article

References (42)

1. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cella anemia. J Clin Invest. 1984;74(2):652-656.
2. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med. 1990;322(15):1037-1045.
3. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea. Effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79(10):2555-2565.
4. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sicklecell anemia. N Engl J Med. 1995;332(20):1317-1322.
5. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996;88(6): 1960-1964.
6. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Blood. 1999;94(5):1550-1554.
7. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematological efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039-2045.
8. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial doppler flow velocities in children with sickle cell anemia. Blood. 2007;110(3):1043-1047.
9. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle cell anemia. J Pediatr 2001;139(6):790-796.
10. Thornburg CD, Dixon N, Burgett S, et al. Hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer. 2009;52(5):609-615.
11. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicenter, randomized, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.
12. Evidence-based management of sickle cell disease. Expert panel report 2014. http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-diseaseguidelines/[nhlbi.nih.gov].
13. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(18):1033-1048.
14. Savage WJ, Buchanan GR, Yawn BP, et al. Evidence gaps in the management of sickle cell disease: a summary of needed research. Am J Hematol 2015;90(4):273-275.
15. Crosby LE, Shook LM, Ware RE, Brinkman WB. Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia. Pediatr Blood Cancer. 2014; Oct 12. doi:10.1002/pbc.25124. [Epub ahead of print]
16. Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr, 1996;128(6):820-828.
17. Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985-4991.
18. Ware RE, Helms RW for the SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119(17): 3925-3932.
19. De Montalembert M, Belloy M, Bernaudin F, et al. Three year follow-up of hydroxyurea treatment in children with sickle cell disease. The French Study Group on Sickle Cell Disease. Am J Pediatr Hematol Oncol. 1997;19(4):313-318.
20. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematol Am Soc Hematol Educ Program. 2009;62-69.
21. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106(7):2269-2275.
22. Wang WC, Langston JW, Steen RG, et al. Abnormalities of the central nervous system in very young children with sickle cell anemia. J Pediatr. 1998;132(6):994-998.
23. DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood. 2012;119(20):4587-4596.
24. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1): 288-294.
25. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5-11.
26. DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371(8):699-710.
27. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122(6):1062-1071.
28. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145(3):346-352.
29. Cunningham-Myrie C, Abdulkadri A, Waugh A, et al. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: a cost effectiveness analysis. Pediatr Blood Cancer. 2015 Apr 30. doi: 10.1002/pbc.25563. [Epub ahead of print]
30. Aygun B, McMurray MA, Schultz WH, et al. for the SWiTCH Investigators. Chronic transfusion standards for children with sickle cell anemia and stroke. Br J Haematol. 2009;145(10):524-528.
31. Aygun B, Wruck L, Schultz WH, et al for the TWiTCH Trial Investigators. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. Am J Hematol. 2012;87(4):428-430.
32. Ware RE, Schultz WH, Yovetich N, et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer. 2011;57(6):1011-1017.
33. Aygun B, Mortier NA, Kesler K, et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. Br J Haematol. 2015;169(2):262-266.
34. Sheehan VA, Luo Z, Flanagan JM, et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. Am J Hematol. 2013;88(7):571-576.
35. Sheehan VA, Crosby JR, Sabo A, et al. Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia. PLoS One 2014;9(10):e110740.
36. Ballas SK, McCarthy WF, Guo N, et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc. 2009;101(10):1046-1051.
37. Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. Human Reproduction Update 2010;16(3):231-245.
38. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331-4336.
39. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med 2013;10(7):e1001484.
40. World Health Organization. Sickle-cell disease: a strategy for the WHO African Region. Report AFR/RC60/8. Geneva, Switzerland: World Health Organization; 2010.
41. Jain DL, Apte M, Colah R, et al. Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience. Indian Pediatr. 2013;50(10):929-933.
42. Hankins JS, McCarville MB, Rankine-Mullings A, et al. Prevention of conversion to abnormal TCD with hydroxyurea in sickle cell anemia: A phase III international randomized clinical trial. Am J Hematol. Published online ahead of print September 28, 2015. doi: 10.1002/ajh.24198.